Trial Profile

A Phase 2a, Open-Label, Multi-Center Study to Assess the Efficacy and Safety of Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Subjects With Locally Advanced and Unresectable or Metastatic NSCLC Previously Treated With Anti-PD-1

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Genetically modified marrow infiltrating lymphocytes WindMIL Therapeutics (Primary) ; Pembrolizumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Sponsors WindMIL Therapeutics

16 Jun 2021 Status changed from recruiting to active, no longer recruiting.
28 May 2021 Planned End Date changed from 1 Jun 2026 to 1 Mar 2027.
28 May 2021 Planned primary completion date changed from 1 Mar 2022 to 1 Aug 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com